“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...

Adults as young as 50 may now qualify for an respiratory synctial virus vaccine if they have certain health conditions.

GSK has applied to the US Food and Drug Administration (FDA) to extend use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults under the age of 50 who are at increased risk of the ...

The update covers the safety and appropriate timing of vaccinations, screening for osteoporosis, cervical cancer, skin cancer ...

GSK plc GSK announced that the FDA has accepted its regulatory filing seeking to expand the use of its RSV vaccine, Arexvy, in adults under 50 who are at a higher risk of the disease. A final decision ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50, down from 60, following ...

Vaccines do much more than prevent specific diseases — their side benefits save children's lives around the world ...

Six in 10 U.S. adults think that AI-generated health information is somewhat or very reliable, a survey from the Annenberg Public Policy Center finds. But nearly half (49%) are not comfortable with ...

If I have sounded like a broken record these past months, it is because these developments in American public health are as ...

Each year, almost 200,000 adults 65 and older are hospitalized due to RSV, and an estimated 14,000 of those cases result in ...

A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa's private sector but not yet in public clinics. The country's advisory group on ...